Study Title
A First-in-Human Study of 89Zr-DFO-REGN5054 (Anti-CD8) Positron Emission Tomography in Patients With Solid Malignancies Treated With Cemiplimab
Study Details
Description:
The primary objective of the study is to determine the safety and tolerability of 89Zr-DFO-REGN5054 alone and in combination with cemiplimab.
Sponsor:
Regeneron Pharmaceuticals
Contacts:
Clinical Trials Administratorclinicaltrials@regeneron.com
844-734-6643
Government Study Link:
NCT05259709 - Click here to see study onClinicalTrials.gov